Cerevast Medical, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cerevast Medical, Inc.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
The 90-day results of CLOTBUST ER, published in The Lancet, show sonothrombolysis to treat acute ischemic stroke is feasible and probably safe, but the trial did not show a clinical benefit of the therapy in conjunction with alteplase treatment.
This week's roundup includes CEO appointments by Eton Pharmaceuticals, the Biotechnology Innovation Organization and Hikma, in addition to various other high-level appointments by Astellas, Akili Interactive Labs and Oxford BioDynamics.
Cerevast Therapeutics is gaining momentum as the company raises new funds and advances enrollment in its pivotal Phase III clinical trial evaluating its Clotbust ER, an ultrasonic head-frame that delivers acoustic energy to the brain to enhance clot dissolution in acute ischemic stroke patients who receive intravenous tPA.
- Rehabilitation Equipment and Devices
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Cerevast Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.